Take the Money and Run Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Take the Money and Run

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: X Y Zebra who wrote (3649)	6/18/2002 8:41:30 AM
From: SusieQ1065	Read Replies (1) of 17639

a little Bio tidbit (from CBSmarketwatch) Biotech weakness was also surfacing. Amgen (AMGN: news, chart, profile) was offered lowered at $42.50 on Instinet in London from a $42.70 close. The stock eased to $42.09 in Germany in euro trading. Biogen (BGEN: news, chart, profile) was around $43.35 in Frankfurt from a $44.01 close. Dealers attributed some of the weakness to a broker comment late Thursday. UBS Warburg started coverage of Biogen at a 'hold' telling clients "growth is elusive" and set a $35 price target on the stock. UBS also started Amgen at a 'buy' with a $47 12-month price target on the stock. UBS told clients that the largest risk to Amgen stock "is the likely possibility that the company will have to bring down financial guidance related to the INMX acquisition."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next